ASX - By Stock
|
AN1 |
Re:
Ann: Organisational Changes
|
|
Biotechasx
|
5 |
1.8K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
5
|
1.8K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Biotechasx
|
2 |
921 |
0 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
2
|
921
|
0
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Letter to Shareholders - AGM
|
|
Biotechasx
|
3 |
1.6K |
7 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
3
|
1.6K
|
7
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Appendix 4E - Preliminary final report-unaudited
|
|
Biotechasx
|
12 |
4.1K |
1 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
12
|
4.1K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
RGS chart thread
|
|
Biotechasx
|
29 |
10K |
3 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
29
|
10K
|
3
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Anagenics Appoints CEO
|
|
Biotechasx
|
33 |
10K |
1 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
33
|
10K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Grant of ASX Waiver
|
|
Biotechasx
|
2 |
1.0K |
2 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
2
|
1.0K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Grant of Options to CEO and Appendix 3G
|
|
Biotechasx
|
1 |
1.0K |
3 |
23/02/22 |
23/02/22 |
ASX - By Stock
|
1
|
1.0K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus Market Update
|
|
Biotechasx
|
11 |
4.0K |
5 |
21/01/22 |
21/01/22 |
ASX - By Stock
|
11
|
4.0K
|
5
|
|
ASX - By Stock
|
CMB |
Re:
RGS chart thread
|
|
Biotechasx
|
29 |
10K |
2 |
05/01/22 |
05/01/22 |
ASX - By Stock
|
29
|
10K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus Market Update
|
|
Biotechasx
|
11 |
4.0K |
3 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
11
|
4.0K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus Corporate Presentation (October 2021)
|
|
Biotechasx
|
4 |
1.4K |
3 |
28/10/21 |
28/10/21 |
ASX - By Stock
|
4
|
1.4K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Appendix 4E - Preliminary final report-unaudited
|
|
Biotechasx
|
24 |
9.6K |
2 |
20/10/21 |
20/10/21 |
ASX - By Stock
|
24
|
9.6K
|
2
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Agreement Signed for Sale of Lyramid Limited
|
|
Biotechasx
|
333 |
55K |
1 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
333
|
55K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Agreement Signed for Sale of Lyramid Limited
|
|
Biotechasx
|
333 |
55K |
2 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
333
|
55K
|
2
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Agreement Signed for Sale of Lyramid Limited
|
|
Biotechasx
|
333 |
55K |
4 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
333
|
55K
|
4
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus Announces Institutional Placement
|
|
Biotechasx
|
55 |
21K |
6 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
55
|
21K
|
6
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Rights Issue Closed with Strong Demand
|
|
Biotechasx
|
154 |
28K |
1 |
08/04/21 |
08/04/21 |
ASX - By Stock
|
154
|
28K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus to be granted key Progenza patent in Europe
|
|
Biotechasx
|
15 |
5.2K |
2 |
16/03/21 |
16/03/21 |
ASX - By Stock
|
15
|
5.2K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus Company Update Investor Webcast Presentation
|
|
Biotechasx
|
10 |
4.4K |
1 |
03/03/21 |
03/03/21 |
ASX - By Stock
|
10
|
4.4K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus Company Update Investor Webcast Presentation
|
|
Biotechasx
|
10 |
4.4K |
3 |
03/03/21 |
03/03/21 |
ASX - By Stock
|
10
|
4.4K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus to be granted new patent to target pain in Japan
|
|
Biotechasx
|
10 |
4.5K |
1 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
10
|
4.5K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: CEO Appointment and Resignation
|
|
Biotechasx
|
73 |
22K |
3 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
73
|
22K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: CEO Appointment and Resignation
|
|
Biotechasx
|
73 |
22K |
4 |
06/01/21 |
06/01/21 |
ASX - By Stock
|
73
|
22K
|
4
|
|
ASX - By Stock
|
CMB |
Re:
Ann: CEO Appointment and Resignation
|
|
Biotechasx
|
73 |
22K |
5 |
28/12/20 |
28/12/20 |
ASX - By Stock
|
73
|
22K
|
5
|
|
ASX - By Stock
|
CSL |
Re:
CSL (ASX:CSL) share price on watch after hints of ‘far more robust’ vaccine
|
|
Biotechasx
|
19 |
7.4K |
0 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
19
|
7.4K
|
0
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Appendix 3Y - Leo Lee
|
|
Biotechasx
|
35 |
9.9K |
1 |
10/12/20 |
10/12/20 |
ASX - By Stock
|
35
|
9.9K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Appendix 3Y - Leo Lee
|
|
Biotechasx
|
35 |
9.9K |
5 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
35
|
9.9K
|
5
|
|
ASX - By Stock
|
CMB |
Re:
Ann: CEO Appointment and Resignation
|
|
Biotechasx
|
73 |
22K |
3 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
73
|
22K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: CEO Appointment and Resignation
|
|
Biotechasx
|
73 |
22K |
2 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
73
|
22K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus to be granted new Sygenus patent in Canada
|
|
Biotechasx
|
41 |
10K |
3 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
41
|
10K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus to be granted new Sygenus patent in Canada
|
|
Biotechasx
|
41 |
10K |
2 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
41
|
10K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus to be granted new Sygenus patent in Canada
|
|
Biotechasx
|
41 |
10K |
5 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
41
|
10K
|
5
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Australian Biomarker Patent Allowed
|
|
Biotechasx
|
6 |
2.1K |
3 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
6
|
2.1K
|
3
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid's Shipment of SARS-CoV-2 Tests Received
|
|
Biotechasx
|
394 |
122K |
4 |
30/09/20 |
30/09/20 |
ASX - By Stock
|
394
|
122K
|
4
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid's Shipment of SARS-CoV-2 Tests Received
|
|
Biotechasx
|
394 |
122K |
4 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
394
|
122K
|
4
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus and Kyocera sign Progenza OA deal
|
|
Biotechasx
|
83 |
26K |
7 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
83
|
26K
|
7
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: CDY Engages Advisers to Facilitate Divestment from Lyramid
|
|
Biotechasx
|
139 |
28K |
0 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
139
|
28K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: CDY Engages Advisers to Facilitate Divestment from Lyramid
|
|
Biotechasx
|
139 |
28K |
10 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
139
|
28K
|
10
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: CDY Engages Advisers to Facilitate Divestment from Lyramid
|
|
Biotechasx
|
139 |
28K |
10 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
139
|
28K
|
10
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus and Kyocera sign Progenza OA deal
|
|
Biotechasx
|
83 |
26K |
3 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
83
|
26K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
breaking out
|
|
Biotechasx
|
32 |
15K |
2 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
32
|
15K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Notice of initial substantial holder - Kirman 2 Pty Ltd
|
|
Biotechasx
|
8 |
2.7K |
5 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
8
|
2.7K
|
5
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Notice of initial substantial holder - Kirman 2 Pty Ltd
|
|
Biotechasx
|
8 |
2.7K |
1 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
8
|
2.7K
|
1
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Appendix 3Y - Leo Lee
|
|
Biotechasx
|
35 |
9.9K |
2 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
35
|
9.9K
|
2
|
|
ASX - By Stock
|
CMB |
Re:
Ann: CEO bonus payment
|
|
Biotechasx
|
4 |
1.8K |
6 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
4
|
1.8K
|
6
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus and Kyocera sign Progenza OA deal
|
|
Biotechasx
|
83 |
26K |
7 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
83
|
26K
|
7
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus and Kyocera sign Progenza OA deal
|
|
Biotechasx
|
83 |
26K |
5 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
83
|
26K
|
5
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus receives milestone payment from Kyocera
|
|
Biotechasx
|
23 |
6.7K |
3 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
23
|
6.7K
|
3
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Regeneus receives milestone payment from Kyocera
|
|
Biotechasx
|
23 |
6.7K |
2 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
23
|
6.7K
|
2
|
|